A debate on government control of drug prices has been brought to the fore. That is, after a bill was introduced by Democratic members of Congress last week to curb prescription drug costs.
As reported by The Washington Post, Rep. Elijah Cummings (D-MD) and Rep. Peter Welch, two of the bill’s co-sponsors, have been in conversation with President Trump about decreasing rising drug costs by allowing the government to negotiate with Medicare. But will the plan create better options for patients or stifle innovation?
Larry speaks with experts from both sides of the aisle to find out more.
Zeke Emanuel, senior fellow at the Center for American Progress and chair of the Department of Medical Ethics and Health Policy at the University of Pennsylvania
Paul Howard, director of health policy and senior fellow at the Manhattan Institute